Bolt-On Acquisitions: Key Considerations For Life Science Executives

By Arda Ural

Given the uncertainty of the past year, it’s no surprise that global M&A plummeted in 2020. But despite the turbulence, total liquidity in the market remained robust and relatively untouched, and one year later, thanks to scientific innovation, we now have a much brighter outlook for market activity.

In fact, our research shows that 43% of life science executives plan to actively pursue acquisitions in the next 12 months. Tellingly, 41% of those we surveyed say bolt-ons will be the deal of choice — suggesting that life science executives should refresh their playbooks for this type of acquisition.